Clin Rheumatol. 2025 Jun 8. doi: 10.1007/s10067-025-07512-x. Online ahead of print.
ABSTRACT
PURPOSE: The pan-immune-inflammation value (PIV) is a promising biomarker that reflects systemic inflammation and aids in disease prognosis. We sought to explore the potential association between PIV and hyperuricemia in the adult population of the USA.
METHODS: The data were collected from the National Health and Nutrition Examination Survey (NHANES) 2007-2018. PIV was calculated as follows: (neutrophil × platelet × monocyte)/lymphocyte (10⁹/L). Hyperuricemia is defined as uric acid levels ≥ 420 mmol/L in males and ≥ 360 mmol/Ls in females. The association between PIV and the prevalence of hyperuricemia, as well as its impact on all-cause and cardiovascular mortality, was investigated.
RESULTS: A total of 31,151 adult participants were included in this study. The prevalence of hyperuricemia increased progressively with higher PIV levels (13.41% vs. 14.87% vs. 15.75% vs. 20.02%, P < 0.001). Participants in the fourth quartile of PIV had a greater risk of hyperuricemia compared to those in the first quartile (OR = 1.19, 95% CI: 1.07-1.32, P = 0.001). Smooth curve fitting also indicated a dose-response relationship between PIV levels and hyperuricemia risk. Additionally, elevated PIV levels were linked to an increased risk of all-cause and cardiovascular mortality in patients with hyperuricemia (P < 0.001).
CONCLUSIONS: PIV is an emerging biomarker reflecting systemic inflammation, with the potential for assessing hyperuricemia and its prognostic risk. Key Points • Pan-immune-inflammation value (PIV) holds potential as an epidemiological tool for analyzing immune-inflammatory responses tied to hyperuricemia and its long-term mortality risk.
PMID:40483638 | DOI:10.1007/s10067-025-07512-x
